National CineMedia (NCMI) Form 144: Proposed 30,971-Share Sale via J.P. Morgan
Rhea-AI Filing Summary
Form 144 filed for National CineMedia, Inc. (NCMI) reports a proposed sale of 30,971 common shares through J.P. Morgan Securities on 09/25/2025 on the Nasdaq with an aggregate market value of $146,493. The shares reported were acquired from the issuer: 28,818 shares from a PSU vest on 08/04/2022, 1,833 shares as compensation on 02/24/2020, and 320 shares as compensation on 12/02/2019. The filer states there were no sales in the past three months to report and makes the standard representation about absence of undisclosed material adverse information.
Positive
- Full disclosure of acquisition history showing dates and nature (PSU vest, compensation) for all shares being sold
- Broker and execution details provided (J.P. Morgan Securities; Nasdaq; execution date 09/25/2025)
- No sales in the past three months reported, indicating this is not part of a rapid disposal sequence
Negative
- None.
Insights
TL;DR: Insider plans a routine sale of 30,971 NCMI shares acquired from compensation and PSU vesting, modest in market value.
The filing documents a single proposed sale of 30,971 common shares valued at $146,493 to execute on 09/25/2025 via J.P. Morgan Securities. Acquisition dates show typical compensation timing and a PSU vesting event; there are no reported sales in the prior three months. This appears to be a routine insider liquidity event rather than a large, potentially market-moving disposal given the small percentage implied by the outstanding share count of 174,065,873. The filing includes the required representation about material nonpublic information.
TL;DR: The disclosure fulfills Rule 144 notice requirements for an insider sale; documentation is standard and complete.
Information provided includes broker, share count, market value, acquisition method, and dates, satisfying the notice elements. The filer confirms no recent sales and makes the customary attestation regarding material information. There is no indication in the filing of reliance on Rule 10b5-1 plans or other atypical arrangements. From a governance standpoint, the form is routine and compliant based on the data presented.